Incyte Announces Abstracts Accepted for Presentation at the 2019 ASCO Annual Meeting and the 24th Congress of EHA
Incyte Corporation (Nasdaq:INCY) announces that multiple abstracts highlighting data from its oncology portfolio will be presented at the upcoming 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held from May 31-June 4, 2019, in Chicago, Illinois; and the 24th Congress of the European Hematology Association (EHA), to be held June 13-16, 2019, in Amsterdam, the Netherlands.
Abstracts accepted for presentation at ASCO feature genomic profiling data from Incyte’s ongoing Phase 2 FIGHT-202 trial evaluating its selective fibroblast growth factor receptor (FGFR) inhibitor, pemigatinib, in patients with cholangiocarcinoma, as well as efficacy and safety data from the Novartis-sponsored GEOMETRY mono-1 trial of capmatinib, the investigational selective MET inhibitor licensed to Novartis by Incyte. Additionally, data to be presented at EHA will showcase the continued study of Incyte’s JAK1/JAK2 inhibitor, ruxolitinib, in myeloproliferative neoplasms (MPNs).
"Our presence at ASCO and EHA illustrates Incyte’s ongoing commitment to discovering and developing therapeutic options that address significant unmet medical needs for patients,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “We are pleased to highlight new data on two investigational medicines – pemigatinib and capmatinib – that were discovered by Incyte scientists and for which we anticipate applications for initial U.S. regulatory approvals later this year, as well as data that furthers our understanding of the treatment of MPNs.”
Key ASCO and EHA abstracts include:
Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): efficacy data from the phase 2 GEOMETRY mono-1 study (Abstract #9004, oral abstract session)
- Monday, June 3, 2019, 9:12 – 9:24 a.m. CT, Hall B1
Comprehensive genomic profiling in FIGHT-202 reveals the landscape of actionable alterations in advanced cholangiocarcinoma (Abstract #4080, poster session)
- Monday, June 3, 2019, 8:00 – 11:00 a.m. CT, Hall A
Impact of myeloproliferative neoplasms (MPNS) and perceptions of treatment goals amongst physicians and patients in 6 countries: an expansion of the MPN Landmark Survey (Abstract #PF681, poster presentation)
- Friday, June 14, 2019, 5:30 – 7:00 p.m. CEST, Poster area
Real-world safety data from a non-interventional long-term post authorization safety study of ruxolitinib in myelofibrosis (Abstract #PF679, poster presentation)
- Friday, June 14, 2019, 5:30 – 7:00 p.m. CEST, Poster area
Safety and efficacy of ruxolitinib (RUX) in patients with myelofibrosis (MF) and anemia (hemoglobin <10g/dL): Results at Week 24 of the REALISE trial (Abstract #PS1465, poster presentation)
- Saturday, June 15, 2019, 5:30 – 7:00 p.m. CEST, Poster area
Where the use of compounds described herein is either investigational or being studied for (a) new use(s), efficacy and safety have not been established, and there is no guarantee that such compounds will become commercially available for the use(s) under investigation.
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company’s website at www.incyte.com.
Follow @Incyte on Twitter at https://twitter.com/Incyte.
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the Company’s development pipeline and whether or when any development compounds will be approved for use in humans anywhere in the world, its presentation plans for the upcoming ASCO and EHA annual meetings and its goal of improving the lives of patients, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments and the risks related to the efficacy or safety of the Company’s development pipeline, the results of further research and development, the high degree of risk and uncertainty associated with drug development, clinical trials and regulatory approval processes, other market or economic factors and competitive and technological advances; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its Form 10-Q for the quarter ending March 31, 2019. Incyte disclaims any intent or obligation to update these forward-looking statements.
+1 302 498 6171
Michael Booth, DPhil
+1 302 498 5914
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sofinnova Partners Raises €333 Million Capital IX Early-Stage Healthcare Fund17.10.2019 06:00:00 CEST | Press release
Sofinnova Partners, a leading European venture capital firm based in Paris, London and Milan and specialized in Life Sciences, announced today the close of its latest early-stage healthcare venture capital fund Sofinnova Capital IX, oversubscribed at €333 million. The firm now has more than €2B under management with more than €1B raised in the last four years across its platform of life sciences funds. Pursuing the strategy it has consistently applied over the years for its flagship early-stage Capital funds, Sofinnova Capital IX will invest in the healthcare industry and more specifically in the biopharmaceutical and medical device sectors. Sofinnova Partners will seek to invest as a founding and lead investor in start-ups and corporate spin-offs, and focus on therapeutic, paradigm-shifting technologies and products alongside visionary entrepreneurs. Sofinnova Capital IX will invest about two thirds of its funds in European companies, and one third outside of Europe, primarily in Nort
Johns Hopkins Center for Health Security, World Economic Forum and Bill & Melinda Gates Foundation Host Pandemic Exercise and Livestream16.10.2019 19:18:00 CEST | Press release
The Johns Hopkins Center for Health Security, with the World Economic Forum and the Bill & Melinda Gates Foundation, will host Event 201 , a multimedia global pandemic exercise on Friday, Oct. 18, 2019, in New York City. The public may register and participate in the simultaneous virtual exercise in English, 8:50 a.m.-12:30 p.m. EDT at centerforhealthsecurity.org/event201/. The exercise underscores the need for global public-private cooperation to mitigate economic and societal impacts of severe pandemics. In recent years, the world has seen a growing number of epidemic events, about 200 per year, which strain limited resources. A large global pandemic would be disruptive to health, economies, and society. Economic studies show that pandemics could be the cause of an average annual economic loss of 0.7% of global GDP—or $570 billion. Event 201, played by 15 leaders of businesses, governments, and public health, will illustrate realistic policy problems that must be addressed under pres
Murray Energy Corporation Extends Forbearance Agreements with its Lenders and Elects Not to Make Interest Payments to Noteholders16.10.2019 17:47:00 CEST | Press release
As previously disclosed, on October 2, 2019 Murray Energy Corporation (“Murray Energy” or “the Company”) entered into forbearance agreements with lenders holding in excess of 50% of outstanding loans under its Superpriority Credit and Guaranty Agreement and with lenders holding in excess of 50% of outstanding loans under its ABL and FILO credit facilities. Under the terms of the forbearance agreements, the lenders agreed to forbear from exercising any and all remedies available to them in respect of any event of default arising from the missed amortization and interest payments due on September 30, 2019. On October 15, 2019, Murray Energy and its lenders amended the previously disclosed forbearance agreements, extending the forbearance period through 11:59 p.m. (New York time) on October 28, 2019, unless further extended. The forbearance agreements will terminate upon the earlier of the end of the forbearance period or the occurrence of a specified forbearance termination event. With d
Tealium Expands Leadership Team, Appoints World-Class Marketing Executive as CMO16.10.2019 15:37:00 CEST | Press release
Tealium, the trusted leader in real-time customer data orchestration, today announced that Heidi Bullock has joined the company as Chief Marketing Officer (CMO). Bullock previously served as CMO at Engagio, and prior to that as Group Vice President of Global Marketing at Marketo. “We are thrilled to have Heidi joining the executive team at Tealium,” said Jeff Lunsford, Chief Executive Officer (CEO) of Tealium. “She is a fantastic addition, not only due to her extensive knowledge in marketing but also her impressive leadership experience in building and scaling high-performance marketing teams. Heidi will undoubtedly help us expand our market position in a high growth market and continue to solidify us as a global leader in the industry.” Most recently she was the CMO of Engagio, where she was responsible for the go-to-market strategy, product marketing, internal sales, corporate communications, and helping create the ABM Automation category. Prior to Engagio, Heidi was the Group Vice P
JD Events: Plant Based World Launches in the UK16.10.2019 14:44:00 CEST | Press release
Following the huge success of the Plant Based World Conference & Expo in New York, organiser JD Events is delighted to announce the launch of Plant Based World Europe in London in 2020. The UK is Europe’s largest market for plant-based foods, valued at £470m versus $4.5bn in the US, and is growing at an exponential rate. Adoption of a plant-based lifestyle is sweeping the globe as people everywhere are becoming aware of the human health, environmental and ethical implications of consuming more plant-based products. One in six food products launched in the UK in 2018 carried a vegan claim. “The fundamental shift away from animal product consumption towards more wholesome, plant-based options is our opportunity as a society to create a healthier world for future generations”, commented Ben Davis, Content & Communications Director, Plant Based World Conference & Expo. “Our goal at PBW is to accelerate this shift by providing a professional platform for the global plant-based market to blo
European DataWarehouse Releases Updated Version of EDITOR as European Commission Publishes RTS on Disclosure16.10.2019 13:31:00 CEST | Press release
The European Commission today published the Regulatory Technical Standards (RTS) on Disclosure Requirements, a key building block of the EU Securitisation Regulation (EU) 2017/2402. Once the European Parliament and the Council endorse the RTS, it will be published in the Official Journal of the European Union (EU). In the absence of objections, the new disclosure requirements, including ESMA’s new reporting templates, will come into force in Q1 2020. European DataWarehouse (ED) has been preparing for the implementation of the new disclosure regime since the Securitisation Regulation entered into force on 17 January 2018, and already offers a number of related services for originators, sponsors and SSPEs. Notably, ED launched a new version of its web-based reporting solution, EDITOR, earlier this week. EDITOR covers all reporting requirements for both public and private ABS and ABCP transactions, including the ability to submit reporting templates in ESMA’s prescribed XML format. Dr. Ch